Saralasin ([Sar1], [Ala8]-Ang II) is a partial agonist of angiotensin II receptors, though it is commonly mistaken as a competitive antagonist.
CAT No: 10-101-304
CAS No: 34273-10-4
Synonyms/Alias: Saralasin;34273-10-4;Saralasina;Saralasine;Saralasinum;Sar-Arg-Val-Tyr-Val-His-Pro-Ala;Saralasinum [INN-Latin];Saralasin [INN:BAN];Saralasine [INN-French];Saralasina [INN-Spanish];DTXSID2046549;(Sar1,Val5,Ala8)-Angiotensin II;CHEMBL938;H2AFV2HE66;1-Sar-8-Ala-angiotensin II;(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid;DTXCID0026549;Angiotensin II, 1-(N-methylglycine)-5-L-valine-8-L-alanine-;(Sar(1),Ala(8))ANGII;(1-(N-Methylglycin) 5-L-valin, 8-L-alanin)angiotensin II;Saralasine (INN-French);Saralasinum (INN-Latin);Saralasina (INN-Spanish);N-(1-(N-(N-(N-(N-(N2-(N-methylglycly)-L-arginyl)-L-valyl)-L-tyrosyl)-L-valyl)-L-histidyl)-L-prolyl)-L-alanine;UNII-H2AFV2HE66;1 Sar 8 Ala Angiotensin II;1-Sar-8-Ala Angiotensin II;Angiotensin II, 1-Sar-8-Ala;(Sar1,Val5,Ala8)Angiotensin II;NCGC00166135-01;(2S)-2-(((2S)-1-((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-5-(diaminomethylideneamino)-2-((2-(methylamino)acetyl)amino)pentanoyl)amino)-3-methylbutanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)-3-methylbutanoyl)amino)-3-(1H-imidazol-5-yl)propanoyl)pyrrolidine-2-carbonyl)amino)propanoic acid;angiotensin II, Sar(1)-Ala(8)-;1 Sarcosine 8 Alanine Angiotensin II;1-Sarcosine-8-Alanine Angiotensin II;Angiotensin II, 1-Sarcosine-8-Alanine;angiotensin II, sarcosyl(1)-alanine(8)-;SARALASIN [INN];SARALASIN [MI];SCHEMBL23;CHEBI:135894;2-((1-(2-((2-((2-((2-((5-(diaminomethylideneamino)-2-((2-methylaminoacetyl)amino)pentanoyl)amino)-3-methylbutanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)-3-methylbutanoyl)amino)-3-(3H-imidazol-4-yl)propanoyl)pyrrolidine-2-carbonyl)amino)propanoic acid;2-[[1-[2-[[2-[[2-[[2-[[5-(diaminomethylideneamino)-2-[(2-methylaminoacetyl)amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(3H-imidazol-4-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid;HY-P0205;Tox21_112332;BDBM50009338;BDBM50229504;AKOS024456428;DB06763;NCGC00167316-01;FS108389;CAS-34273-10-4;CS-0021297;NS00073478;Sar-Arg-Val-Tyr-Val-His-Pro-Ala (sarlasin);[Sar1-Arg2-Val3-Tyr4-Val5-His6-Pro7-Ala8];Q410298;(Sar 1,Val5,Ala8)-Angiotensin II trifluoroacetate salt;ANGIOTENSIN II, 1-SARCOSINE-5-L-VALINE-8-L-ALANINE-;Saralasin;Sar-Arg-Val-Tyr-Val-His-Pro-Ala-OH trifluoroacetate salt;L-ALANINE, N-METHYLGLYCYL-L-ARGINYL-L-VALYL-L-TYROSYL-L-VALYL-L-HISTIDYL-L-PROLYL-;(S)-2-((S)-1-((6S,9S,12S,15S,18S)-18-((1H-imidazol-4-yl)methyl)-6-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9,15-diisopropyl-4,7,10,13,16-pentaoxo-2,5,8,11,14,17-hexaazanonadecane)pyrrolidine-2-carboxamido)propanoic acid;(S)-2-((S)-1-((S)-2-((S)-2-((S)-2-((S)-2-((S)-5-(diaminomethyleneamino)-2-(2-(methylamino)acetamido)pentanamido)-3-methylbutanamido)-3-(4-hydroxyphenyl)propanamido)-3-methylbutanamido)-3-(1H-imidazol-5-yl)propanoyl)pyrrolidine-5-carboxamido)propanoic acid;60173-70-8;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C42H65N13O10 |
M.W/Mr. | 912 |
Sequence | One Letter Code:GRVYVHPA Three Letter Code:H-Sar-Arg-Val-Tyr-Val-His-Pro-Ala-OH |
Purity | ≥97% (HPLC) |
Activity | Agonist |
Target | Angiotensin II Receptors |
Source# | Synthetic |
Long-term Storage Conditions | 1 mg/ml in water |
Shipping Condition | +20°C (International: -20°C) |
InChI | InChI=1S/C42H65N13O10/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47)/t24-,28-,29-,30-,31-,33-,34-/m0/s1 |
InChI Key | PFGWGEPQIUAZME-NXSMLHPHSA-N |
Canonical SMILES | CC(C)C(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C(C)C)C(=O)NC(CC2=CN=CN2)C(=O)N3CCCC3C(=O)NC(C)C(=O)O)NC(=O)C(CCCN=C(N)N)NC(=O)CNC |
Isomeric SMILES | C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC |
1. Implications of ligand-receptor binding kinetics on GLP-1R signalling
3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com